Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

543 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Schmid P, et al. Among authors: wallwiener d. J Clin Oncol. 2007 Jun 20;25(18):2509-15. doi: 10.1200/JCO.2006.08.8534. J Clin Oncol. 2007. PMID: 17577027 Clinical Trial.
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P, et al. Among authors: wallwiener d. Anticancer Res. 2002 Jul-Aug;22(4):2325-32. Anticancer Res. 2002. PMID: 12174922 Clinical Trial.
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen Ch, Ebert A, Harbeck N, Jackisch C, Heilman V, Emons G, Wallwiener D, Wiese W, Blohmer JU, Höffken K, Kuhn W, Reichardt P, Muscholl M, Pauschinger M, Langer B, Lück HJ. Untch M, et al. Among authors: wallwiener d. Eur J Cancer. 2004 May;40(7):988-97. doi: 10.1016/j.ejca.2004.01.011. Eur J Cancer. 2004. PMID: 15093573 Clinical Trial.
Anthracycline and trastuzumab in breast cancer treatment.
Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B. Untch M, et al. Among authors: wallwiener d. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):59-64. Oncology (Williston Park). 2004. PMID: 15685838 Free article. Clinical Trial.
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.
Oskay-Ozcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Bamberg M, Wallwiener D, Overkamp F, Diedrich K, von Minckwitz G, Höffken K, Seeber S, Mirz R, Sehouli J. Oskay-Ozcelik G, et al. Among authors: wallwiener d. Ann Oncol. 2007 Mar;18(3):479-84. doi: 10.1093/annonc/mdl456. Epub 2007 Feb 1. Ann Oncol. 2007. PMID: 17272832 Free article.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group. Kenemans P, et al. Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23. Lancet Oncol. 2009. PMID: 19167925 Free article. Clinical Trial.
543 results